Caffeine for treatment of Parkinson disease: a randomized controlled trial.
Identifieur interne : 000A37 ( PubMed/Corpus ); précédent : 000A36; suivant : 000A38Caffeine for treatment of Parkinson disease: a randomized controlled trial.
Auteurs : Ronald B. Postuma ; Anthony E. Lang ; Renato P. Munhoz ; Katia Charland ; Amelie Pelletier ; Mariana Moscovich ; Luciane Filla ; Debora Zanatta ; Silvia Rios Romenets ; Robert Altman ; Rosa Chuang ; Binit ShahSource :
- Neurology [ 1526-632X ] ; 2012.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Caffeine, Central Nervous System Stimulants.
- drug therapy : Fatigue, Parkinson Disease.
- Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Quality of Life, Severity of Illness Index, Treatment Outcome.
Abstract
Epidemiologic studies consistently link caffeine, a nonselective adenosine antagonist, to lower risk of Parkinson disease (PD). However, the symptomatic effects of caffeine in PD have not been adequately evaluated.
DOI: 10.1212/WNL.0b013e318263570d
PubMed: 22855866
Links to Exploration step
pubmed:22855866Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Caffeine for treatment of Parkinson disease: a randomized controlled trial.</title><author><name sortKey="Postuma, Ronald B" sort="Postuma, Ronald B" uniqKey="Postuma R" first="Ronald B" last="Postuma">Ronald B. Postuma</name><affiliation><nlm:affiliation>Department of Neurology, McGill University, Montreal General Hospital, Montreal, Canada. ronald.postuma@mcgill.ca</nlm:affiliation></affiliation></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E" last="Lang">Anthony E. Lang</name></author><author><name sortKey="Munhoz, Renato P" sort="Munhoz, Renato P" uniqKey="Munhoz R" first="Renato P" last="Munhoz">Renato P. Munhoz</name></author><author><name sortKey="Charland, Katia" sort="Charland, Katia" uniqKey="Charland K" first="Katia" last="Charland">Katia Charland</name></author><author><name sortKey="Pelletier, Amelie" sort="Pelletier, Amelie" uniqKey="Pelletier A" first="Amelie" last="Pelletier">Amelie Pelletier</name></author><author><name sortKey="Moscovich, Mariana" sort="Moscovich, Mariana" uniqKey="Moscovich M" first="Mariana" last="Moscovich">Mariana Moscovich</name></author><author><name sortKey="Filla, Luciane" sort="Filla, Luciane" uniqKey="Filla L" first="Luciane" last="Filla">Luciane Filla</name></author><author><name sortKey="Zanatta, Debora" sort="Zanatta, Debora" uniqKey="Zanatta D" first="Debora" last="Zanatta">Debora Zanatta</name></author><author><name sortKey="Rios Romenets, Silvia" sort="Rios Romenets, Silvia" uniqKey="Rios Romenets S" first="Silvia" last="Rios Romenets">Silvia Rios Romenets</name></author><author><name sortKey="Altman, Robert" sort="Altman, Robert" uniqKey="Altman R" first="Robert" last="Altman">Robert Altman</name></author><author><name sortKey="Chuang, Rosa" sort="Chuang, Rosa" uniqKey="Chuang R" first="Rosa" last="Chuang">Rosa Chuang</name></author><author><name sortKey="Shah, Binit" sort="Shah, Binit" uniqKey="Shah B" first="Binit" last="Shah">Binit Shah</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="RBID">pubmed:22855866</idno><idno type="pmid">22855866</idno><idno type="doi">10.1212/WNL.0b013e318263570d</idno><idno type="wicri:Area/PubMed/Corpus">000A37</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A37</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Caffeine for treatment of Parkinson disease: a randomized controlled trial.</title><author><name sortKey="Postuma, Ronald B" sort="Postuma, Ronald B" uniqKey="Postuma R" first="Ronald B" last="Postuma">Ronald B. Postuma</name><affiliation><nlm:affiliation>Department of Neurology, McGill University, Montreal General Hospital, Montreal, Canada. ronald.postuma@mcgill.ca</nlm:affiliation></affiliation></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E" last="Lang">Anthony E. Lang</name></author><author><name sortKey="Munhoz, Renato P" sort="Munhoz, Renato P" uniqKey="Munhoz R" first="Renato P" last="Munhoz">Renato P. Munhoz</name></author><author><name sortKey="Charland, Katia" sort="Charland, Katia" uniqKey="Charland K" first="Katia" last="Charland">Katia Charland</name></author><author><name sortKey="Pelletier, Amelie" sort="Pelletier, Amelie" uniqKey="Pelletier A" first="Amelie" last="Pelletier">Amelie Pelletier</name></author><author><name sortKey="Moscovich, Mariana" sort="Moscovich, Mariana" uniqKey="Moscovich M" first="Mariana" last="Moscovich">Mariana Moscovich</name></author><author><name sortKey="Filla, Luciane" sort="Filla, Luciane" uniqKey="Filla L" first="Luciane" last="Filla">Luciane Filla</name></author><author><name sortKey="Zanatta, Debora" sort="Zanatta, Debora" uniqKey="Zanatta D" first="Debora" last="Zanatta">Debora Zanatta</name></author><author><name sortKey="Rios Romenets, Silvia" sort="Rios Romenets, Silvia" uniqKey="Rios Romenets S" first="Silvia" last="Rios Romenets">Silvia Rios Romenets</name></author><author><name sortKey="Altman, Robert" sort="Altman, Robert" uniqKey="Altman R" first="Robert" last="Altman">Robert Altman</name></author><author><name sortKey="Chuang, Rosa" sort="Chuang, Rosa" uniqKey="Chuang R" first="Rosa" last="Chuang">Rosa Chuang</name></author><author><name sortKey="Shah, Binit" sort="Shah, Binit" uniqKey="Shah B" first="Binit" last="Shah">Binit Shah</name></author></analytic><series><title level="j">Neurology</title><idno type="eISSN">1526-632X</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Caffeine (therapeutic use)</term><term>Central Nervous System Stimulants (therapeutic use)</term><term>Fatigue (drug therapy)</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (drug therapy)</term><term>Quality of Life</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Caffeine</term><term>Central Nervous System Stimulants</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Fatigue</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Quality of Life</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Epidemiologic studies consistently link caffeine, a nonselective adenosine antagonist, to lower risk of Parkinson disease (PD). However, the symptomatic effects of caffeine in PD have not been adequately evaluated.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22855866</PMID><DateCreated><Year>2012</Year><Month>08</Month><Day>14</Day></DateCreated><DateCompleted><Year>2012</Year><Month>10</Month><Day>24</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>7</Issue><PubDate><Year>2012</Year><Month>Aug</Month><Day>14</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Caffeine for treatment of Parkinson disease: a randomized controlled trial.</ArticleTitle><Pagination><MedlinePgn>651-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0b013e318263570d</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Epidemiologic studies consistently link caffeine, a nonselective adenosine antagonist, to lower risk of Parkinson disease (PD). However, the symptomatic effects of caffeine in PD have not been adequately evaluated.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a 6-week randomized controlled trial of caffeine in PD to assess effects upon daytime somnolence, motor severity, and other nonmotor features. Patients with PD with daytime somnolence (Epworth >10) were given caffeine 100 mg twice daily ×3 weeks, then 200 mg twice daily ×3 weeks, or matching placebo. The primary outcome was the Epworth Sleepiness Scale score. Secondary outcomes included motor severity, sleep markers, fatigue, depression, and quality of life. Effects of caffeine were analyzed with Bayesian hierarchical models, adjusting for study site, baseline scores, age, and sex.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 61 patients, 31 were randomized to placebo and 30 to caffeine. On the primary intention-to-treat analysis, caffeine resulted in a nonsignificant reduction in Epworth Sleepiness Scale score (-1.71 points; 95% confidence interval [CI] -3.57, 0.13). However, somnolence improved on the Clinical Global Impression of Change (+0.64; 0.16, 1.13, intention-to-treat), with significant reduction in Epworth Sleepiness Scale score on per-protocol analysis (-1.97; -3.87, -0.05). Caffeine reduced the total Unified Parkinson's Disease Rating Scale score (-4.69 points; -7.7, -1.6) and the objective motor component (-3.15 points; -5.50, -0.83). Other than modest improvement in global health measures, there were no changes in quality of life, depression, or sleep quality. Adverse events were comparable in caffeine and placebo groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Caffeine provided only equivocal borderline improvement in excessive somnolence in PD, but improved objective motor measures. These potential motor benefits suggest that a larger long-term trial of caffeine is warranted.</AbstractText><AbstractText Label="CLASSIFICATION OF EVIDENCE" NlmCategory="METHODS">This study provides Class I evidence that caffeine, up to 200 mg BID for 6 weeks, had no significant benefit on excessive daytime sleepiness in patients with PD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Postuma</LastName><ForeName>Ronald B</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Department of Neurology, McGill University, Montreal General Hospital, Montreal, Canada. ronald.postuma@mcgill.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lang</LastName><ForeName>Anthony E</ForeName><Initials>AE</Initials></Author><Author ValidYN="Y"><LastName>Munhoz</LastName><ForeName>Renato P</ForeName><Initials>RP</Initials></Author><Author ValidYN="Y"><LastName>Charland</LastName><ForeName>Katia</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Pelletier</LastName><ForeName>Amelie</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Moscovich</LastName><ForeName>Mariana</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Filla</LastName><ForeName>Luciane</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Zanatta</LastName><ForeName>Debora</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Rios Romenets</LastName><ForeName>Silvia</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Altman</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Chuang</LastName><ForeName>Rosa</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Binit</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>08</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000697">Central Nervous System Stimulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>3G6A5W338E</RegistryNumber><NameOfSubstance UI="D002110">Caffeine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Pharmacol Ther. 2005 Mar;105(3):267-310</RefSource><PMID Version="1">15737407</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Expert Opin Investig Drugs. 2005 Jun;14(6):729-38</RefSource><PMID Version="1">16004599</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 2005 Dec;76(12):1636-9</RefSource><PMID Version="1">16291885</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurosci Lett. 2006 Jan 23;393(1):31-5</RefSource><PMID Version="1">16236444</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2006 Mar;59(3):559-62</RefSource><PMID Version="1">16489611</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Neurol. 2006 Jun;5(6):525-35</RefSource><PMID Version="1">16713924</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2006 Sep 12;67(5):897-9</RefSource><PMID Version="1">16966563</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Sleep Res. 2007 Mar;16(1):102-9</RefSource><PMID Version="1">17309769</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2007 Apr 15;22(5):710-2</RefSource><PMID Version="1">17373724</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacogenet Genomics. 2007 Nov;17(11):1001-5</RefSource><PMID Version="1">18075470</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2008 Jan 15;70(3):231-6</RefSource><PMID Version="1">18195269</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2009 Dec;15 Suppl 4:S28-32</RefSource><PMID Version="1">20123553</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2010 Jan;16(1):16-20</RefSource><PMID Version="1">19616987</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2010 Jul 30;25(10):1437-43</RefSource><PMID Version="1">20629136</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2010 Jul;16(6):423-6</RefSource><PMID Version="1">20338800</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Neurol. 2011 Mar;10(3):221-9</RefSource><PMID Version="1">21315654</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2011 Nov;26(13):2427-31</RefSource><PMID Version="1">21953603</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2003 May 13;60(9):1553-4</RefSource><PMID Version="1">12743258</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2002 Apr 23;58(8):1154-60</RefSource><PMID Version="1">11971080</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2002 Sep;52(3):276-84</RefSource><PMID Version="1">12205639</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Sleep. 2002 Dec15;25(8):905-9</RefSource><PMID Version="1">12489899</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Food Addit Contam. 2003 Jan;20(1):1-30</RefSource><PMID Version="1">12519715</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1346-51</RefSource><PMID Version="1">12538862</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2003 Mar;18(3):287-93</RefSource><PMID Version="1">12621632</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuropharmacology. 2003 Sep;45(4):493-503</RefSource><PMID Version="1">12907310</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2003 Dec 9;61(11 Suppl 6):S5-9</RefSource><PMID Version="1">14663001</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2003 Dec 9;61(11 Suppl 6):S51-4</RefSource><PMID Version="1">14663011</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2004 Jan;61(1):97-102</RefSource><PMID Version="1">14732626</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 1975 Aug;25(8):722-4</RefSource><PMID Version="1">125389</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 1976 Aug;26(8):741-3</RefSource><PMID Version="1">181692</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Psychiatry Res. 1989 May;28(2):193-213</RefSource><PMID Version="1">2748771</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 1989 Oct;46(10):1121-3</RefSource><PMID Version="1">2803071</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Sleep. 1991 Dec;14(6):540-5</RefSource><PMID Version="1">1798888</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Med Care. 1992 Jun;30(6):473-83</RefSource><PMID Version="1">1593914</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Food Chem Toxicol. 1996 Jan;34(1):119-29</RefSource><PMID Version="1">8603790</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol. 1998 May;245 Suppl 1:S10-4</RefSource><PMID Version="1">9617716</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Gen Psychiatry. 1961 Jun;4:561-71</RefSource><PMID Version="1">13688369</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2012 Aug 14;79(7):616-8</RefSource><PMID Version="1">22855870</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Neurology. 2012 Oct 16;79(16):1744</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002110" MajorTopicYN="N">Caffeine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000697" MajorTopicYN="N">Central Nervous System Stimulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC3414662</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22855866</ArticleId><ArticleId IdType="pii">WNL.0b013e318263570d</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e318263570d</ArticleId><ArticleId IdType="pmc">PMC3414662</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A37 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000A37 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:22855866
|texte= Caffeine for treatment of Parkinson disease: a randomized controlled trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:22855866" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |